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Objective: This randomized, placebo-controlled, crossover trial assessed the lipid-altering efﬁcacy
of a softgel capsule dietary supplement, providing esteriﬁed plant sterols/stanols 1.8 g/d, in 28
participants (w75% women) with primary hypercholesterolemia (fasting low-density lipoprotein
cholesterol [LDL-C] levels 130 and <220 mg/dL), a mean age of 58.4 y, and a mean body mass
index of 27.9 kg/m2.
Methods: After a 5-wk National Cholesterol Education Program (NCEP) Therapeutic Lifestyle
Changes (TLC) diet and a single-blinded placebo lead-in, subjects received double-blinded placebo
or sterol/stanol softgel capsules for 6 wk and then crossed over to the opposite product for 6 wk
while continuing the TLC diet. Fasting lipids were assessed in duplicate at the end of the diet lead-
in (baseline) and the end of each treatment.
Results: The mean baseline lipid concentrations (milligrams per deciliter) were 223 for total
cholesterol (TC), 179 for non–high-density lipoprotein cholesterol (non-HDL-C), 154 for low-
density lipoprotein cholesterol, 44 for HDL-C, 125 for triacylglycerols, and 5.2 for TC/HDL-C.
Differences from the control responses (plant sterol/stanol minus control) in the per-protocol
sample were signiﬁcant (P < 0.05) for LDL-C (9.2%), non-HDL-C (9.0%), TC (7.4%), TC/HDL-C
(5.4%), and triacylglycerols (9.1%). The HDL-C responses were not signiﬁcantly different
between treatments.
Conclusion: The incorporation of softgel capsules providing esteriﬁed plant sterols/stanols 1.8 g/d
into the NCEP TLC diet produced favorable changes in atherogenic lipoprotein cholesterol levels in
these subjects with hypercholesterolemia.
 2013 Elsevier Inc. All rights reserved.Introduction
Plant sterols and stanols (sterols containing additional
hydrogen) occur naturally and have a similar structure to
cholesterol [1,2]. Plant sterols/stanols have been shown to
decrease cholesterol absorptionbycompetingwith cholesterol for
incorporation into micelles in the intestinal lumen and for trans-
port across the brush border by Niemann Pick C1-like 1 trans-
porters [3–5]. Plant sterol/stanol accumulation in the enterocyte
also appears to trigger the greater production of transporters
(adenosine triphosphate binding cassette transporters G5 ande, California.
þ630-617-2001.
ll rights reserved.G8), which move sterols out of the enterocyte and into the
intestinal lumen [3,5]. The net result is increased fecal cholesterol
excretion [5,6], leading to decreased hepatic cholesterol content
that in turn stimulates the upregulation of hepatic low-density
lipoprotein (LDL) receptor number, thus increasing the removal
of LDL and other apolipoprotein B–containing lipoproteins from
the circulation [5]. Plant sterols/stanols also have been reported to
have an antioxidant effect against the lipid peroxidation of LDL in
laboratory and animal studies [7].
In a typical Western diet, approximately 150 to 400 mg
of plant sterols/stanols is consumed daily in food, and this level
of intake does not substantially affect blood cholesterol
concentrations [8,9]. However, at higher intakes, the consump-
tion of plant sterols or stanols lowers total cholesterol (TC),
non–high-density lipoprotein cholesterol (non-HDL-C), and LDL
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data from plant sterol and stanol trials have suggested that LDL-C
is decreased by approximately 4% to 5% with each gram of plant
sterol or stanol consumed in the range of 1 to 3 g/d, and higher
baseline LDL-C levels typically have been associated with larger
decreases [2,12,13].
Commercially available products containing plant sterols
and/or stanols, in their free and ester forms, include margarine-
type spreads, yogurt and yogurt-based drinks, orange juice, and
dietary supplement tablets and capsules. Most clinical exami-
nations of the effects of plant sterols/stanols on lipid concen-
trations have used food vehicles, and fewer have investigated
the effects of plant sterols or stanols administered in tablets and
capsules [1,2,12–24]. Results from these investigations have
suggested that food and supplement forms are successful in
lowering circulating cholesterol concentrations. However, the
use of plant sterol/stanol-containing tablets or capsules is
particularly appealing because of the ease of incorporating these
into a cholesterol-lowering regimen compared with the dietary
adjustments necessary to incorporate food products [2,13].
This trial was undertaken to assess the efﬁcacy of the
consumption of softgel capsules providing esteriﬁed plant
sterols/stanols 1.8 g/d, incorporated into the National Cholesterol
Education Program (NCEP) Therapeutic Lifestyle Changes (TLC)
diet [11], for improving the lipid proﬁle of men and womenwith
primary hypercholesterolemia. Previously, non-esteriﬁed sito-
stanol-containing phytosterols 1.7 and 1.8 g/d administered in
margarine and chocolate have been shown to decrease LDL-C by
up to 15.5% [14,15].
Materials and methods
Study design
This was a randomized crossover study conducted from September 2009 to
February 2010, consisting of a 5-wk diet plus a single-blinded placebo softgel
capsule lead-in, followed by two double-blinded 6-wk treatment periods
during which subjects received softgel capsules providing esteriﬁed sterol/
stanols 2.9 g/d (equivalent to non-esteriﬁed plant sterol/stanols 1.8 g/d) or
control softgel capsules. Subjects completed three screening/lead-in/baseline
visits (weeks 5, 1, and 0) and four treatment visits (weeks 5, 6, 11, and 12).
The study was conducted at two clinical research centers (Biofortis-Provident
Clinical Research in Addison, IL and Bloomington, IN, USA) according to Good
Clinical Practice Guidelines, the Declaration of Helsinki (2000), and the US 21
Code of Federal Regulations. Signed written informed consent for the study was
obtained from all subjects before the protocol-speciﬁc procedures were carried
out and the subjects were informed of their right to withdraw from the study at
any time.
Subjects
Men and women 21 to 79 y of age, inclusive, each with a fasting LDL-C level
from at least 130 to lower than 220 mg/dL and in good general health based on
medical history and routine laboratory tests, were eligible for the study. Indi-
viduals were excluded from participation if they had a body mass index higher
than 42.0 kg/m2, a fasting blood glucose level of at least 126 mg/dL or diabetes
mellitus, a resting systolic blood pressure of at least 160 mmHg and/or a diastolic
blood pressure of at least 100 mmHg, or coronary heart disease or a coronary
heart disease risk equivalent [11]. Additional exclusion criteria included a history
of extreme dietary habits, eating disorders, alcoholism, cancer, or any clinically
important cardiovascular disorders. The use of any medications, dietary
supplements, or fortiﬁed foods with lipid-altering effects, including sterol and
stanol products, was excluded for at least 4 wk before study entry (week 1), as
was use of weight-loss drugs or programs and a recent body weight change
greater than 4.5 kg.
Study products and diet instruction
After the diet and single-blinded control study product lead-in, the subjects
were randomly assigned to receive, in a double-blinded manner, esteriﬁed sterol/
stanol softgel capsules (0.45 mg/capsule) or control softgel capsules (matchedplacebo that contained soybean oil and medium-chain triacylglycerols [TGs]
from coconut oil) for 6 wk (ﬁrst treatment period) and then crossed over to
receive the opposite study product for 6 wk (second treatment period). The
softgel capsules contained 81% plant sterol (predominantly sitosterol) and 19%
plant stanol (predominantly sitostanol). Subjects were instructed to swallow
whole, with water or another beverage, four softgel capsules daily (twowith each
of two meals) at consistent times each day. Compliance with the active and
control softgel capsules was assessed by counting the unused study product
returned to the clinic. In addition, subjects were instructed to maintain their
usual physical activity patterns throughout the trial.
Beginning at week 5 and throughout the study, subjects were counseled to
follow the weight-maintenance version of the TLC diet created by the NCEP and
handouts were provided to reinforce the diet instructions [11]. To evaluate
compliance with the TLC diet, diet records were completed on 3 consecutive days
(2 weekdays and 1 weekend day) at baseline and the end of each treatment
period. Daily intakes of energy and selected nutrients were calculated from these
records using Food Processor SQL 10.4 (ESHA Research, Salem, OR, USA). In
addition, subjects were instructed to maintain their usual physical activity
patterns throughout the study period.
Laboratory measurements
Clinical laboratory measurements in fasting (9–15 h) blood samples collected
in duplicate at baseline (weeks1 and 0) and at the end of each treatment period
(weeks 5 and 6, weeks 11 and 12) were conducted by the Elmhurst Memorial
Hospital Laboratory (Elmhurst, IL, USA) according to the Standardization
Program of the Centers for Disease Control and Prevention and the National
Heart, Lung, and Blood Institute. Lipoprotein lipid assessments (milligrams per
deciliter) included TC, LDL-C, HDL-C, non-HDL-C (calculated as TC minus HDL-C),
TG, and the TC/HDL-C ratio. The LDL-C concentrationwas calculated according to
the Friedewald equation as: LDL-C ¼ TC  HDL-C  TG/5 [25]. Because this
equation is not valid when the TG concentration is above 400 mg/dL, the LDL-C
values were not calculated in the few instances when subjects had values in this
range.
Statistical analyses
Statistical analyses were completed in SAS 9.2 (SAS Institute, Cary, NC, USA).
Analyses were performed on an efﬁcacy evaluable sample that included all
subjects who were randomized and provided at least one fasting lipid proﬁle
during each treatment condition after randomization. Per-protocol analyses also
were performed in a subset of the efﬁcacy evaluable sample that excluded
subjects with poor compliance, signiﬁcant protocol violations, or circumstances
during the study that could confound the evaluation of the study product. All
decisions about exclusion from the per-protocol sample were documented before
breaking the treatment code. The per-protocol results are described in this
report, except where indicated otherwise. A sample of 24 evaluable subjects was
calculated to provide 90% power to detect a difference between the active and
control treatment conditions of 7% in LDL-C change from baseline with a two-
tailed a level of 0.05, assuming a pooled standard deviation of 10% for the LDL-
C response. A larger sample of 34 subjects was randomized to allow for subject
attrition and non-compliance.
Baseline characteristics for subjects in the two treatment sequences were
compared using unpaired t tests (continuous variables) or the Fisher exact test
(categorical variables). Repeated measures analysis of covariance was used to
compare lipids and dietary intake responses (changes or percentages of change
from baseline) for the two treatment conditions (active and control) using the
baseline value as a covariate. The initial model included the subject as a random
effect and terms for treatment condition, sequence, site and treatment-by-site
and treatment-by-sequence interactions. If an interaction term for a variable
was not statistically signiﬁcant (P > 0.05), it was dropped from the ﬁnal model.
The examination of responses by sequence suggested that nomaterial differences
were present that would bring into question the appropriateness of pooling data
from the two sequence groups. Residuals from the ﬁnal model were examined to
assess normality; if clear evidence of non-normality was present, rank trans-
formations were used in the ﬁnal models.
An additional analysis of covariance was conducted using the results of the
equation of Yu et al. [26] for estimating changes in lipid concentrations in
response to a dietary alteration according to the diet record results, with and
without an adjustment for dietary cholesterol intake based on the dietary
cholesterol term in the equation of Hegsted et al. [27]. This was done to assess
possible confounding by dietary changes during the treatment periods.
Safety analyses were performed on the sample that included all subjects who
were randomized and consumed at least one dose of the study product. Safety
assessments included an evaluation of treatment-emergent adverse events
compared between the two treatment conditions using the McNemar test, and
changes in vital sign measurements were analyzed with a repeated measures
analysis of covariance as described earlier.
Table 1
Subject characteristics at baseline (n ¼ 28)*
Characteristics
Men 7 (25%)
Women 21 (75%)
Race/ethnicity
Non-Hispanic white 25 (89%)
Asian or Paciﬁc Islander 2 (7%)
Black/African American 1 (4%)
Smoking status
Non-smoker 26 (93%)
Current Smoker 2 (7%)
Age (y) 58.4  1.4
Weight (kg) 78.9  2.6
Body mass index (kg/m2) 27.9  0.8
Systolic blood pressure (mmHg) 118.9  1.9
Diastolic blood pressure (mmHg) 73.0  1.6
Fasting glucose (mg/dL) 99.8  1.9
Values are presented as number (percentage) or mean  SEM
* Results for the two treatment sequences were pooled and the presented
values are for the per-protocol analysis sample.
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Subjects and demographics
Sixty-one subjects were screened, 36 of whom entered and
completed the ﬁrst treatment phase (Fig. 1). Two subjects did not
complete the second treatment phase and were excluded from
the efﬁcacy analyses. One withdrew consent, and the other had
an adverse event of gas, which began during the placebo lead-in
period shortly after visit 1 and continued throughout the study,
eventually leading to the subject’s discontinuation during the
second treatment period. Six additional subjects were removed
from the per-protocol population because of less than 80%
compliance with the study product consumption (n ¼ 2), upper
respiratory infection (n ¼ 1), excessive alcohol consumption
(n ¼ 1), exclusionary supplement use (n ¼ 1), and an instance in
which a subject ran out of the study product before the last clinic
visit (n ¼ 1). The present results are for the 28 subjects (con-
trol:plant sterol/stanol, n ¼ 14; plant sterol/stanol:control, n ¼
14) in the per-protocol sample except as otherwise indicated. The
demographic and baseline characteristics of the subjects are
presented in Table 1. The subjects were predominantly women
(75%), of non-Hispanic white race/ethnicity (89%), and non-
smokers (93%). The participants had a mean age of 58.4 y and
a mean body mass index of 27.9 kg/m2. Compliance with the
active and control capsules was 98.4% and 96.9% of expected
doses, respectively (P ¼ 0.296).
Lipids
Fasting plasma lipids at baseline, the percentages of change
from baseline for the active and control treatments, and differ-
ences in responses between conditions in the per-protocol sample
are presented in Table 2. Mean differences from the control in
responses (plant sterol/stanol minus control) were signiﬁcant (P
< 0.05) for LDL-C (9.2%), non-HDL-C (9.0%), TC (7.4%), TC/
HDL-C (5.4%), and TG (9.1%). The HDL-C responses were not
signiﬁcantly different between the treatment conditions. The
LDL-C and non-HDL-C concentrations (milligrams per deciliter) at
baseline and at the ends of the active and control conditions in the
per-protocol sample are presented in Figure 2. In the efﬁcacy
evaluable population, mean differences from the control in
responses were similar but somewhat smaller than those in the
per-protocol population: LDL-C (7.4%), non-HDL-C (7.3%), TCScreened 
N = 61 
Randomized 
n = 36 
Control/Active 
n = 18 
Active/Control 
n = 18 
Started Treatment Phase I: n = 18 
Completed Treatment Phase I: n = 18 
Started Treatment Phase I: n = 18 
Completed Treatment Phase I: n = 18 
Started Treatment Phase II: n = 18 
Completed Treatment Phase II: n = 16 
Started Treatment Phase II: n = 18 
Completed Treatment Phase II: n = 18 
Fig. 1. Participant ﬂow through the study.(5.8%), and TC/HDL-C (5.7%; P < 0.05 for all comparisons). The
TG and HDL-C responses were not signiﬁcantly different between
the treatment conditions in the efﬁcacy evaluable analyses
(7.3%, P ¼ 0.103, and 0.2%, P ¼ 0.934, respectively).
Diet
There were no signiﬁcant differences between the active and
control conditions in total reported energy intake; percentages of
intake from carbohydrate, protein, total fat, and saturated, mono-
unsaturated, and polyunsaturated fatty acids; and intakes of
dietary ﬁber, soluble ﬁber, or cholesterol (Table 3). The analysis of
covariance to adjust for predicted effects of non-signiﬁcant differ-
ences in dietary fatty acid and cholesterol intakes did not materi-
ally alter the estimates of the treatment effects (data not shown).
Vital signs, body weight, and safety
Mean body weight changes in the control and active periods
were 0.41 and 0.32 kg, respectively (P ¼ 0.239), and mean
systolic and diastolic blood pressures changed no more than 1
mmHg throughout the study (P > 0.05 for treatment effect for
the two comparisons). Adverse events assessed at each clinic
visit were reported by six subjects (8.3%) during the active periodTable 2
Fasting lipids at baseline, percentages of change from baseline, and differences in
responses between treatments*
Parameter Baseline
(mg/dL)y
Active
(%D)z
Control
(%D)z
Difference in
response (%)x
P
LDL-C 153.6 (2.5) 4.1 (1.1) 5.1 (2.0) 9.2 <0.001
Non–HDL-C 178.6 (3.4) 4.4 (1.3) 4.6 (2.0) 9.0 <0.001
TC 222.5 (2.9) 3.3 (1.0) 4.0 (1.5) 7.4 <0.001
HDL-C 44.0 (1.3) 0.9 (2.1) 2.5 (1.8) 1.6 0.382
TG 124.6 (9.7) 4.4 (4.6) 4.7 (5.3) 9.1 0.042
TC/HDL-C 5.19 (0.17) 3.1 (2.2) 2.4 (2.4) 5.4 0.005
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; TC, total cholesterol; TG, triacylglycerols; %D, percentage of change
Values are presented as mean (SEM)
* Results for the two treatment sequences were pooled (n ¼ 28, per-protocol
analysis sample). Adjusting for differences in dietary intake did not signiﬁ-
cantly alter the results.
y Average of values at weeks 1 and 0.
z Percentage of change from baseline to the average of values at the last 2 wk of
each treatment period (weeks 5 and 6 and weeks 11 and 12).
x Active percentage of change minus control percentage of change.
*p < 0.001 vs. control
Baseline Active Control
120
130
140
150
160
170
180
190
200
Non-HDL-C
LDL-C
*
*m
g/
dL
Fig. 2. LDL-C and non-HDL-C (milligrams per deciliter) at baseline (average of
values at weeks 1 and 0) and after treatment (average of values at weeks 5 and 6
and at weeks 11 and 12) with active treatment (esteriﬁed plant sterol/stanol softgel
capsules 1.8 g/d) or control treatment (matched placebo softgel capsules). Values
are presented as mean  SEM. * P < 0.001 for the difference between treatments in
the percentage of change from baseline to the end of treatment. LDL-C, low-density
lipoprotein cholesterol; non-HDL-C, non–high-density lipoprotein cholesterol.
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Treatment-emergent adverse events, reported by one subject
each, included fatigue, gingivitis, headache, hypertonia, infec-
tion, and insomnia during the active treatment condition and
myalgia, rhinitis, salivary duct obstruction, and upper respiratory
infection during the control treatment condition. None of the
adverse events was serious and all were reported to be mild or
moderate in severity. All adverse events were classiﬁed by the
study physicians as not related or unlikely to be related to the
study products. One subject withdrew from the study during the
second treatment period because of an adverse event of gas that
started during the placebo lead-in. This event was classiﬁed by
the study physician as being possibly related to the lead-in
(placebo) study product.Discussion
The ﬁndings of the present study show that esteriﬁed plant
sterols/stanols 1.8 g/d administered orally in softgel capsules
twice per day, as part of the NCEP TLC diet, produced signiﬁcant
decreases in atherogenic lipoprotein lipids (LDL-C, non-HDL-C,
and TC) in these subjects with hypercholesterolemia. The
product was well-tolerated and the LDL-C lowering produced by
the plant sterol/stanol dose administered in the present trial
(9.2% in the per-protocol sample and 7.4% in the efﬁcacy
evaluable sample) was very similar to the predicted valueTable 3
Intakes of energy and macronutrients at baseline and during the active and
control periods*
Parameter Baseline Active Control P
Energy (kcal/d) 1831 (102.4) 1700 (96.1) 1695 (80.9) 0.379
Carbohydrate (% energy) 50.3 (1.6) 48.9 (1.8) 51.9 (1.7) 0.173
Protein (% energy) 17.8 (0.8) 17.8 (0.8) 17.4 (0.6) 0.759
Total fat (% energy) 32.0 (1.2) 33.4 (1.3) 31.2 (1.4) 0.191
SFAs (% energy) 10.2 (0.6) 10.1 (0.5) 9.6 (0.6) 0.369
PUFAs (% energy) 4.2 (0.3) 4.4 (0.4) 4.7 (0.3) 0.515
MUFAs (% energy) 7.7 (0.5) 8.6 (0.6) 9.1 (0.7) 0.555
Dietary ﬁber (g/d) 20.7 (2.0) 19.1 (1.8) 20.2 (2.1) 0.324
Soluble ﬁber (g/d) 2.1 (0.3) 2.3 (0.3) 2.5 (0.4) 0.953
Cholesterol (mg/d) 218.8 (20.6) 244.9 (28.6) 213.8 (23.4) 0.184
MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs,
saturated fatty acids
Values are presented as mean (SEM)
* Results for the two treatment sequences were pooled (n ¼ 28, per-protocol
analysis sample).(8.5%) based on a dose–response equation published by
Demonty et al. [13].
Because plant sterols/stanols primarily decrease circulating
cholesterol concentrations by inhibiting the absorption of
cholesterol in the small intestine, characteristics such as whether
the plant sterols/stanols are free or esteriﬁed, the vehicle in
which delivered, and the level of solubilization within that
vehicle are important for determining their lipid-lowering efﬁ-
cacy [1]. Clinical trials of plant sterols/stanols have examined
them in a wide variety of foods and in dietary supplement tablet
or capsule forms [1,2,13]. The available evidence suggests that
the type of food vehicle to which the plant sterols/stanols are
added (e.g., fat-based versus non–fat-based, dairy versus
non-dairy) does not materially affect the response [2,13], but few
studies have administered plant sterols and stanols in tablets and
capsules [1,19–24]. In 2005, McPherson et al. [20] reported that
a 6-wk treatment with rapidly disintegrating stanol lecithin
tablets (stanols 1.26 g/d) resulted in a 10.4% greater decrease in
LDL-C versus placebo (P ¼ 0.01), whereas slowly disintegrating
capsules providing stanols 1.01 g/d had no effects on lipids. A
further examination of the dispersible plant sterol tablets (soy
stanols 1.8 g/d) added to statin therapy for 6 wk was also shown
to decrease LDL-C concentration (9.1% greater than with statin
therapy alone, P ¼ 0.007) [21]. A study conducted by Acuff et al.
[22] demonstrated the efﬁcacy of plant sterol ester 1.3 g/d
administered in a capsule (without a dietary intervention) for
lowering plasma LDL-C in 16 subjects with hypercholesterol-
emia. After a 4-wk treatment period, LDL-C was signiﬁcantly (P<
0.05) decreased by 4% compared with placebo. Carr et al. [23]
reported an 11% decrease from baseline LDL-C in 32 normo-
and hypercholesterolemic adults after a 4-wk treatment period
of plant sterol esters 3 g/d administered in a stearate-enriched
capsule as a supplement to their typical diets.
Although effective, phytosterol-containing foods may be
difﬁcult for individuals to incorporate into a cholesterol-lowering
diet without altering the macronutrient intake and/or distribu-
tion [1,23,28]. The use of a plant sterol/stanol softgel capsule
supplementmay be amore convenient option thatmight increase
compliance during long-term use compared with the types of
dietary changes needed to incorporate phytosterol-containing
foods. Long-term compliance is particularly important when
considering the potential for an LDL-C decrease to affect
a decrease in coronary heart disease risk. Results from clinical
intervention trials have indicated that although each 1% decrease
in LDL-C decreases the cardiovascular event risk by approximately
1% in the intermediate term (w5 y), lower levels of atherogenic
lipoprotein cholesterol maintained over decades might be asso-
ciated with greater event risk decreases in the range of 2% to 3%
for each 1% lower level of LDL-C [29,30].
Although subjects were asked to maintain consistent physical
activity patterns throughout the study period, no physical
activity questionnaire or diary was used. This lack of quantiﬁ-
cation of physical activity is a possible limitation of the study.
However, physical activity, in the absence of weight change,
mainly affects TG and HDL-C levels and has little inﬂuence on
LDL-C [31,32]. Thus, physical activity changes were unlikely to
have confounded the primary study results.
Conclusion
The daily incorporation of four dietary supplement softgel
capsules (two with each of two meals), providing esteriﬁed plant
sterols/stanols 1.8 g/d (sterol/stanol esters w2.9 g/d) into the
NCEP TLC diet, a dosage that is within the range (1–3 g) for which
K. C. Maki et al. / Nutrition 29 (2013) 96–100100the response is fairly linear [12,13], produced favorable changes
in atherogenic lipoprotein cholesterol levels in subjects with
hypercholesterolemia similar to those expected based onprevious
meta-analyses [2,12,13,33]. The long-term plant sterol/stanol
use would be expected to decrease the risk for cardiovascular
disease [34].
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